EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of Lemborexant for Insomnia Patients With Nocturia—A Prospective Study

Yoshikazu Togo iD, Yohei Kaizuka, Seiji Nagasawa, Keisuke Kajio, Nobuyuki Kondoh, Keizo Taguchi

LUTS: Lower Urinary Tract Symptoms · 2024

DOI: 10.1111/luts.12534 ↗

Kurz gefasst

Fachartikel in der Zeitschrift LUTS: Lower Urinary Tract Symptoms, 2024. Verfasst von Yoshikazu Togo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kawanishi City Medical Center, Hyogo, Japan. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders, Nocturia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Nocturia is considered a clinical problem when nocturnal urinary frequency is two or more times. For affected patients, development of depression, falling, and increased mortality rate are matters of concern. The present study investigated the efficacy and safety of lemborexant for insomnia patients with nocturia.

Methods

Insomnia patients (Athens Insomnia Scale [AIS] ≥ 6) who typically awoke twice or more during the night to urinate and were examined at our institutions from June 2021 to December 2022 were enrolled. Each was administrated 5 mg of lemborexant, one tablet, daily for 4 weeks. Total AIS score, nocturia frequency, individual frequency‐volume chart findings, and N‐QOL score were examined before and after administration.

Results

Of the 37 patients recruited, 5 were excluded, thus 32 were enrolled and subjected to analyses. Following lemborexant therapy, the mean AIS total score was significantly decreased from 11.4 to 7.8 ( p < 0.01) as was mean number of nocturia episodes from 3.4 to 2.3 ( p < 0.001). Furthermore, the mean single voided urine volume at night was significantly increased from 182.5 to 225.3 mL ( p < 0.001)and mean period of undisturbed sleep was significantly extended from 105.3 to 174.8 min ( p < 0.001), while mean total N‐QOL score was significantly improved from 49.6% to 64.8% ( p < 0.001). As for adverse events, mild somnolence was observed in three cases.

Conclusions

Lemborexant may be effective and safe for use in insomniac patients with nocturia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sleep Initiation and Maintenance DisordersNocturiaHumansMaleFemaleProspective StudiesAgedMiddle AgedTreatment OutcomeQuality of LifePyridinesPyrimidines

Stichwörter der Autor:innen

efficacyinsomnialemborexantnocturiaorexin receptor antagonist

Substanzen

lemborexantPyridinesPyrimidines

Autor:innen und Institutionen

  • Department of Urology, Kawanishi City Medical Center, Hyogo, Japan.
  • Department of Palliative Medicine, Kyoritsu Kinen Hospital, Hyogo, Japan.
  • Taguchi Urology Clinic, Hyogo, Japan.

ORCID-Profile: Yoshikazu Togo

Zitieren

APA

Togo, Y., Kaizuka, Y., Nagasawa, S., Kajio, K., Kondoh, N., & Taguchi, K. (2024). Efficacy and Safety of Lemborexant for Insomnia Patients With Nocturia—A Prospective Study. LUTS: Lower Urinary Tract Symptoms. https://doi.org/10.1111/luts.12534

Vancouver

Togo Y, Kaizuka Y, Nagasawa S, Kajio K, Kondoh N, Taguchi K. Efficacy and Safety of Lemborexant for Insomnia Patients With Nocturia—A Prospective Study. LUTS: Lower Urinary Tract Symptoms. 2024. doi:10.1111/luts.12534

BibTeX
@article{Togo2024,
  author = {Togo, Yoshikazu and Kaizuka, Yohei and Nagasawa, Seiji and Kajio, Keisuke and Kondoh, Nobuyuki and Taguchi, Keizo},
  title = {Efficacy and Safety of Lemborexant for Insomnia Patients With Nocturia—A Prospective Study},
  journal = {LUTS: Lower Urinary Tract Symptoms},
  year = {2024},
  doi = {10.1111/luts.12534}
}
Kostenlos starten →